Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
- Batlle-López, Ana
- De Villambrosía, Sonia González
- Mazorra, Francisco
- Malatxeberria, Sefora
- Sáez, Anabel
- Montalban, Carlos
- Sánchez, Lydia
- Garcia, Juan F.
- González-Barca, Eva
- López, Andrés
- Ruiz-Marcellan,
- Mollejo, Manuela
- Grande, Carlos
- Richards,
- Hsi,
- Tzankov, Alexandar
- Visco, Carlo
- Xu-Monette, Zijun Y.
- Cao, Xin
- Young, Ken H.
- Piris, Miguel Angel
- Conde, Eulogio
- Montes-Moreno, Santiago
DOIAbstract
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using three available immunohistochemical algorithms was evaluated in TMA-arranged tissue samples from 297 patients with de novo DLBCL treated by chemoimmunotherapy (R-CHOP and R-CHOP-like regimens). Additionally, the prognostic impacts of MYC, BCL2, IRF4 and BCL6 abnormalities detected by FISH, the relationship between the immunohistochemical COO classification and the immunohistochemical expression of MYC, BCL2 and pSTAT3 proteins and clinical data were...
Add to ORKG